This webinar will introduce innovative chemically modified oligonucleotide tools designed to address complex disorders, including cancer and associated drug resistance challenges while overcoming the limitations of oligonucleotide therapeutics.
Among the array of oligonucleotide tools presented, particular emphasis will be placed on innovative multi-target nanostructures. These nanostructures are uniquely crafted to deliver multiple oligonucleotide drugs in a single dose, each tailored to act against distinct therapeutic targets.
Additionally, the webinar will delve into the functionalization of these nanostructures with accessory molecules like fluorophores and targeting peptides, which facilitate monitoring of their specific delivery to tumors.
Key Learning Topics
- Exploring novel chemical modification approaches to enhance the biostability of oligonucleotides.
- Understanding the functionalization of therapeutic oligonucleotides with adjunct molecules, such as targeting peptides, to facilitate their selective delivery to tumors.
- Investigating multi-target approaches for delivering multiple oligonucleotide drugs in a single dose.
What to Expect
This webinar will showcase new chemical modification approaches to:
- Increase the resistance of oligonucleotide drugs to 3’-exonuclease degradation.
- Create new robust siRNA prodrugs that can act as substrates for Dicer.
- Combine multiple oligonucleotide drugs into one single structure that can be selectively cleaved by specific intracellular stimuli, such as endogenous enzymes.
About the Speakers
Montserrat Terrazas earned her PhD degree from the University of Barcelona (UB) in 2006. Following this, she undertook postdoctoral research at KU Leuven, Stanford University, and IQAC-CSIC. From 2014 to 2020, she held the position of Miguel Servet Fellow at IRB-Barcelona. In 2021, she was appointed as an Associate Professor at UB.
Martial Piotto earned his Ph.D. in NMR spectroscopy from Purdue University, USA, under the supervision of Professor D. Gorenstein. He subsequently joined Bruker France as the head of NMR applications, where he contributed to various aspects of NMR spectroscopy, particularly focusing on developing new pulse sequences and HRMAS technology. Over the years, he grew interested in the application of NMR in the pharmaceutical and medical fields. His work currently focuses on the characterization of Biologics (mAb, vaccines, and therapeutic oligonucleotides) by combining NMR and multivariate statistical tools.